Bayer faces image issues for Yaz, Yasmin brands

The New York Times took a look at Bayer HealthCare's Yaz and Yasmin in a September 25 story, following the company's recent marketing and...

The New York Times took a look at Bayer HealthCare's Yaz and Yasmin in a September 25 story, following the company's recent marketing and image issues for the popular birth control brands.

In question are safety concerns about the drug's higher risk for blood clots and strokes (compared to other birth control pills) as well as FDA citations for improper marketing and quality control procedures at one of its plants.

The Times writes: "But even if Bayer can adequately respond to the safety and other concerns, some industry analysts say that the avalanche of criticism could tarnish the Yaz line’s image."

On September 26, it was reported that Swiss health regulators were investigating Yaz's role in the death of a young woman.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.